Page A1 | e-Edition | rockymounttelegram com rockymounttelegram.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rockymounttelegram.com Daily Mail and Mail on Sunday newspapers.
A man who frequently speaks at City Council regular meetings recently renewed his previous questioning about the status of mammogram equipment at the Opportunities Industrialization Centerâs specialty care center at the Rocky Mount Event Center.
And this time, the speaker, Samuel Battle, received a more detailed update from Councilman Reuben Blackwell, who also is president and CEO of the OIC.
The OIC seeks to help provide residents with employment training and health care.
During the public input phase of the Dec. 14 council regular meeting, Battle approached the speakerâs podium to comment about a variety of topics.
While at the podium, Battle said, âIâm still worried about that machine that OIC got that ainât up and running â and weâve been talking about this for the last two years.â
Under-recognition of Symptoms May Be Common in Breast Cancer Patients Receiving Radiation
Symptom under-recognition may be more common among younger patients and Black patients
Getty Images
December 14, 2020 Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was common in reports of pain, pruritus, edema and fatigue, with younger patients and Black patients having significantly increased odds of symptom under-recognition, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11. Recognizing side effects is necessary for physicians to provide supportive care to help patients manage their symptoms, said Reshma Jagsi, M.D., D.Phil, the Newman Family Professor and deputy chair of the Department of Radiation Oncology and director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan.
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with node-positive disease
- New meta-analysis of data from more than 10,000 patients with node-negative disease, including the results of TAILORx, supports the Oncotype DX Breast Recurrence Score® test as the standard of care genomic test in early-stage, invasive breast cancer
News provided by
Share this article
MADISON, Wis., Dec. 11, 2020 /PRNewswire/